- Galectin Therapeutics (NASDAQ:GALT) and Providence Cancer Institute have received notice of issuance of U.S. Patent Number 10,398,778 titled "Method for Enhancing Specific Immunotherapies in Cancer Treatment.”
- The patent, in effect until 2033, covers method of use of Company's drug candidate, belapectin (GR-MD-02), as a means to enhance the effectiveness of specific immunotherapies in cancer treatment.
Galectin Therapeutics and Providence Cancer Institute nab new patent in U.S.
Recommended For You
About GALT Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
GALT | - | - |
Galectin Therapeutics Inc. |